Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2024

16-11-2023 | Endoscopy | Review

Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms

Authors: Xinrui Guo, Xiaohan Zhao, Gang Huang, Yanbo Yu

Published in: Digestive Diseases and Sciences | Issue 1/2024

Login to get access

Abstract

Gastric neuroendocrine neoplasms refer to a group of diseases that are relatively rare. They can be classified into three subtypes based on their clinical and histopathological features, and there are significant differences in diagnosis, treatment, and prognosis among the different subtypes. The incidence of gastric neuroendocrine neoplasms has been increasing globally in recent years with the localized disease being particularly evident. Gastrointestinal endoscopy is of irreplaceable importance for the diagnosis and management of g-NENs. Endoscopy with biopsy is the gold standard for the diagnosis of g-NENs. Ultrasound endoscopy can assess the depth of tumor invasion and the presence of lymphatic metastases, which is important for the development of treatment strategies. Meanwhile, for some small and low-risk lesions, endoscopic surveillance or endoscopic resection has satisfactory therapeutic results and prognosis. This means that even though the incidence has increased, advances in endoscopic techniques have allowed more patients to adopt a relatively conservative treatment strategy. However, the criteria for patients suitable for endoscopic surveillance or endoscopic resection remain controversial.
Literature
1.
go back to reference Modlin IM, Kidd M, Latich I et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717–1751.PubMedCrossRef Modlin IM, Kidd M, Latich I et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717–1751.PubMedCrossRef
2.
go back to reference Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335–1342.PubMedPubMedCentralCrossRef Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335–1342.PubMedPubMedCentralCrossRef
3.
go back to reference Grozinsky-Glasberg S, Alexandraki KI, Angelousi A et al. Gastric carcinoids. Endocrinol Metab Clin N Am 2018;47:645–660.CrossRef Grozinsky-Glasberg S, Alexandraki KI, Angelousi A et al. Gastric carcinoids. Endocrinol Metab Clin N Am 2018;47:645–660.CrossRef
4.
go back to reference Papaefthymiou A, Laskaratos FM, Koffas A et al. State of the art in endoscopic therapy for the management of gastroenteropancreatic neuroendocrine tumors. Curr Treat Opt Oncol 2022;23:1014–1034.CrossRef Papaefthymiou A, Laskaratos FM, Koffas A et al. State of the art in endoscopic therapy for the management of gastroenteropancreatic neuroendocrine tumors. Curr Treat Opt Oncol 2022;23:1014–1034.CrossRef
5.
go back to reference Delle Fave G, O’Toole D, Sundin A et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016;103:119–124.PubMedCrossRef Delle Fave G, O’Toole D, Sundin A et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016;103:119–124.PubMedCrossRef
6.
go back to reference Yang Z, Wang W, Lu J et al. Gastric neuroendocrine tumors (G-Nets): incidence, prognosis and recent trend toward improved survival. Cell Physiol Biochem 2018;45:389–396.PubMedCrossRef Yang Z, Wang W, Lu J et al. Gastric neuroendocrine tumors (G-Nets): incidence, prognosis and recent trend toward improved survival. Cell Physiol Biochem 2018;45:389–396.PubMedCrossRef
8.
go back to reference Chauhan A, Kohn E, Del Rivero J. Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence. JAMA Oncol 2020;6:21–22.PubMedPubMedCentralCrossRef Chauhan A, Kohn E, Del Rivero J. Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence. JAMA Oncol 2020;6:21–22.PubMedPubMedCentralCrossRef
9.
go back to reference Chen WF, Zhou PH, Li QL et al. Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. Sci World J 2012;2012:869769.CrossRef Chen WF, Zhou PH, Li QL et al. Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. Sci World J 2012;2012:869769.CrossRef
10.
go back to reference Hu P, Bai J, Liu M et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer 2020;23:591–599.PubMedPubMedCentralCrossRef Hu P, Bai J, Liu M et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer 2020;23:591–599.PubMedPubMedCentralCrossRef
11.
go back to reference Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017;29:11–16.PubMedCrossRef Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017;29:11–16.PubMedCrossRef
12.
go back to reference Nagtegaal ID, Odze RD, Klimstra D et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182–188.PubMedCrossRef Nagtegaal ID, Odze RD, Klimstra D et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182–188.PubMedCrossRef
13.
go back to reference Zhu X, Jing H, Yao T. Clinical characteristics of early neuroendocrine carcinoma in stomach: a case report and review of literature. Medicine (Baltimore) 2019;98:e16638.PubMedCrossRef Zhu X, Jing H, Yao T. Clinical characteristics of early neuroendocrine carcinoma in stomach: a case report and review of literature. Medicine (Baltimore) 2019;98:e16638.PubMedCrossRef
14.
go back to reference Deprez PH, Moons LMG, O’Toole D et al. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2022;54:412–429.PubMedCrossRef Deprez PH, Moons LMG, O’Toole D et al. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2022;54:412–429.PubMedCrossRef
15.
go back to reference Esposito G, Angeletti S, Cazzato M et al. Narrow band imaging characteristics of gastric polypoid lesions: a single-center prospective pilot study. Eur J Gastroenterol Hepatol 2020;32:701–705.PubMedCrossRef Esposito G, Angeletti S, Cazzato M et al. Narrow band imaging characteristics of gastric polypoid lesions: a single-center prospective pilot study. Eur J Gastroenterol Hepatol 2020;32:701–705.PubMedCrossRef
16.
go back to reference Rinke A, Auernhammer CJ, Bodei L et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768–1781.PubMedCrossRef Rinke A, Auernhammer CJ, Bodei L et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768–1781.PubMedCrossRef
17.
go back to reference Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Curr Gastroenterol Rep 2019;21:13.PubMedCrossRef Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Curr Gastroenterol Rep 2019;21:13.PubMedCrossRef
18.
go back to reference Kim SY, Shim KN, Lee JH et al. Comparison of the diagnostic ability of endoscopic ultrasonography and abdominopelvic computed tomography in the diagnosis of gastric subepithelial tumors. Clin Endosc 2019;52:565–573.PubMedPubMedCentralCrossRef Kim SY, Shim KN, Lee JH et al. Comparison of the diagnostic ability of endoscopic ultrasonography and abdominopelvic computed tomography in the diagnosis of gastric subepithelial tumors. Clin Endosc 2019;52:565–573.PubMedPubMedCentralCrossRef
20.
go back to reference Puli SR, Kalva N, Bechtold ML et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis. World J Gastroenterol 2013;19:3678–3684.PubMedPubMedCentralCrossRef Puli SR, Kalva N, Bechtold ML et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis. World J Gastroenterol 2013;19:3678–3684.PubMedPubMedCentralCrossRef
21.
22.
go back to reference Rossi RE, Elvevi A, Gallo C et al. Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: where we are. World J Gastroenterol 2022;28:3258–3273.PubMedPubMedCentralCrossRef Rossi RE, Elvevi A, Gallo C et al. Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: where we are. World J Gastroenterol 2022;28:3258–3273.PubMedPubMedCentralCrossRef
24.
go back to reference Lahner E, Galli G, Esposito G et al. Updated features associated with type 1 gastric carcinoids patients: a single-center study. Scand J Gastroenterol 2014;49:1447–1455.PubMedCrossRef Lahner E, Galli G, Esposito G et al. Updated features associated with type 1 gastric carcinoids patients: a single-center study. Scand J Gastroenterol 2014;49:1447–1455.PubMedCrossRef
26.
go back to reference Sato Y, Imamura H, Kaizaki Y et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc 2014;26:377–384.PubMedCrossRef Sato Y, Imamura H, Kaizaki Y et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc 2014;26:377–384.PubMedCrossRef
27.
go back to reference Grozinsky-Glasberg S, Thomas D, Strosberg JR et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol 2013;19:8687–8695.PubMedPubMedCentralCrossRef Grozinsky-Glasberg S, Thomas D, Strosberg JR et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol 2013;19:8687–8695.PubMedPubMedCentralCrossRef
28.
go back to reference Vanoli A, La Rosa S, Miceli E et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology 2018;107:114–126.PubMedCrossRef Vanoli A, La Rosa S, Miceli E et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology 2018;107:114–126.PubMedCrossRef
29.
go back to reference Tsolakis AV, Ragkousi A, Vujasinovic M et al. Gastric neuroendocrine neoplasms type 1: a systematic review and meta-analysis. World J Gastroenterol 2019;25:5376–5387.PubMedPubMedCentralCrossRef Tsolakis AV, Ragkousi A, Vujasinovic M et al. Gastric neuroendocrine neoplasms type 1: a systematic review and meta-analysis. World J Gastroenterol 2019;25:5376–5387.PubMedPubMedCentralCrossRef
30.
go back to reference Banks M, Graham D, Jansen M et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019;68:1545–1575.PubMedCrossRef Banks M, Graham D, Jansen M et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019;68:1545–1575.PubMedCrossRef
31.
go back to reference Pimentel-Nunes P, Libanio D, Marcos-Pinto R et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019;51:365–388.PubMedCrossRef Pimentel-Nunes P, Libanio D, Marcos-Pinto R et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019;51:365–388.PubMedCrossRef
32.
go back to reference Chin JL, O’Connell J, Muldoon C et al. Selective resection of type 1 gastric neuroendocrine neoplasms and the risk of progression in an endoscopic surveillance programme. Dig Surg 2021;38:38–45.PubMedCrossRef Chin JL, O’Connell J, Muldoon C et al. Selective resection of type 1 gastric neuroendocrine neoplasms and the risk of progression in an endoscopic surveillance programme. Dig Surg 2021;38:38–45.PubMedCrossRef
34.
go back to reference Esposito G, Cazzato M, Rinzivillo M et al. Management of type-I gastric neuroendocrine neoplasms: a 10-years prospective single centre study. Dig Liver Dis 2022;54:890–895.PubMedCrossRef Esposito G, Cazzato M, Rinzivillo M et al. Management of type-I gastric neuroendocrine neoplasms: a 10-years prospective single centre study. Dig Liver Dis 2022;54:890–895.PubMedCrossRef
35.
go back to reference Chung CS, Tsai CL, Chu YY et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: a Digestive Endoscopy Society of Tawian (DEST). Medicine (Baltimore) 2018;97:e12101.PubMedCrossRef Chung CS, Tsai CL, Chu YY et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: a Digestive Endoscopy Society of Tawian (DEST). Medicine (Baltimore) 2018;97:e12101.PubMedCrossRef
36.
go back to reference Daskalakis K, Tsoli M, Karapanagioti A et al. Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 2019;91:534–543.PubMedCrossRef Daskalakis K, Tsoli M, Karapanagioti A et al. Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 2019;91:534–543.PubMedCrossRef
37.
go back to reference Campana D, Ravizza D, Ferolla P et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 2016;51:131–139.PubMedCrossRef Campana D, Ravizza D, Ferolla P et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 2016;51:131–139.PubMedCrossRef
38.
go back to reference Exarchou K, Howes N, Pritchard DM. Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours. Aliment Pharmacol Ther 2020;51:1247–1267.PubMedCrossRef Exarchou K, Howes N, Pritchard DM. Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours. Aliment Pharmacol Ther 2020;51:1247–1267.PubMedCrossRef
39.
go back to reference Roberto GA, Rodrigues CMB, Peixoto RD et al. Gastric neuroendocrine tumor: a practical literature review. World J Gastrointest Oncol 2020;12:850–856.PubMedPubMedCentralCrossRef Roberto GA, Rodrigues CMB, Peixoto RD et al. Gastric neuroendocrine tumor: a practical literature review. World J Gastrointest Oncol 2020;12:850–856.PubMedPubMedCentralCrossRef
40.
go back to reference Putzer D, Schullian P, Jaschke W et al. NEN: advancement in diagnosis and minimally invasive therapy. Rofo 2020;192:422–430.PubMedCrossRef Putzer D, Schullian P, Jaschke W et al. NEN: advancement in diagnosis and minimally invasive therapy. Rofo 2020;192:422–430.PubMedCrossRef
41.
go back to reference Postlewait LM, Baptiste GG, Ethun CG et al. A 15-year experience with gastric neuroendocrine tumors: does type make a difference? J Surg Oncol 2016;114:576–580.PubMedCrossRef Postlewait LM, Baptiste GG, Ethun CG et al. A 15-year experience with gastric neuroendocrine tumors: does type make a difference? J Surg Oncol 2016;114:576–580.PubMedCrossRef
42.
go back to reference Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372–2377.PubMedCrossRef Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372–2377.PubMedCrossRef
43.
go back to reference Panzuto F, Campana D, Fazio N et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2012;96:32–40.PubMedCrossRef Panzuto F, Campana D, Fazio N et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2012;96:32–40.PubMedCrossRef
44.
go back to reference Pape UF, Berndt U, Muller-Nordhorn J et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083–1097.PubMedCrossRef Pape UF, Berndt U, Muller-Nordhorn J et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083–1097.PubMedCrossRef
45.
go back to reference Panzuto F, Campana D, Massironi S et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: a multicentre retrospective study. Dig Liver Dis 2019;51:1456–1460.PubMedCrossRef Panzuto F, Campana D, Massironi S et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: a multicentre retrospective study. Dig Liver Dis 2019;51:1456–1460.PubMedCrossRef
46.
go back to reference Hanna A, Kim-Kiselak C, Tang R et al. Gastric neuroendocrine tumors: reappraisal of type in predicting outcome. Ann Surg Oncol 2021;28:8838–8846.PubMedCrossRef Hanna A, Kim-Kiselak C, Tang R et al. Gastric neuroendocrine tumors: reappraisal of type in predicting outcome. Ann Surg Oncol 2021;28:8838–8846.PubMedCrossRef
47.
go back to reference Hirasawa T, Yamamoto N, Sano T. Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study. Dig Endosc 2021;33:408–417.PubMedCrossRef Hirasawa T, Yamamoto N, Sano T. Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study. Dig Endosc 2021;33:408–417.PubMedCrossRef
48.
go back to reference Min BH, Hong M, Lee JH et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg 2018;105:1480–1486.PubMedCrossRef Min BH, Hong M, Lee JH et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg 2018;105:1480–1486.PubMedCrossRef
49.
50.
go back to reference Exarchou K, Kamieniarz L, Tsoli M et al. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine 2021;74:421–429.PubMedCrossRef Exarchou K, Kamieniarz L, Tsoli M et al. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine 2021;74:421–429.PubMedCrossRef
51.
go back to reference Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005;103:1587–1595.PubMedCrossRef Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005;103:1587–1595.PubMedCrossRef
52.
go back to reference Li YL, Qiu XD, Chen J et al. Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours. World J Gastrointest Oncol 2020;12:1416–1427.PubMedPubMedCentralCrossRef Li YL, Qiu XD, Chen J et al. Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours. World J Gastrointest Oncol 2020;12:1416–1427.PubMedPubMedCentralCrossRef
54.
go back to reference Sivandzadeh GR, Ejtehadi F, Shoaee S et al. Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors. BMC Gastroenterol 2021;21:238.PubMedPubMedCentralCrossRef Sivandzadeh GR, Ejtehadi F, Shoaee S et al. Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors. BMC Gastroenterol 2021;21:238.PubMedPubMedCentralCrossRef
55.
go back to reference Zhong DD, Shao LM, Cai JT. Endoscopic mucosal resection vs endoscopic submucosal dissection for rectal carcinoid tumours: a systematic review and meta-analysis. Colorectal Dis 2013;15:283–291.PubMedCrossRef Zhong DD, Shao LM, Cai JT. Endoscopic mucosal resection vs endoscopic submucosal dissection for rectal carcinoid tumours: a systematic review and meta-analysis. Colorectal Dis 2013;15:283–291.PubMedCrossRef
56.
go back to reference Zhou X, Xie H, Xie L et al. Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol 2014;29:259–268.PubMedCrossRef Zhou X, Xie H, Xie L et al. Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol 2014;29:259–268.PubMedCrossRef
57.
go back to reference Sun W, Wu S, Han X et al. Effectiveness of endoscopic treatment for gastrointestinal neuroendocrine tumors: a retrospective study. Medicine (Baltimore) 2016;95:e3308.PubMedCrossRef Sun W, Wu S, Han X et al. Effectiveness of endoscopic treatment for gastrointestinal neuroendocrine tumors: a retrospective study. Medicine (Baltimore) 2016;95:e3308.PubMedCrossRef
58.
go back to reference Chen X, Li B, Wang S et al. Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China. Scand J Gastroenterol 2019;54:384–389.PubMedCrossRef Chen X, Li B, Wang S et al. Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China. Scand J Gastroenterol 2019;54:384–389.PubMedCrossRef
60.
go back to reference Zhang D, Lin Q, Shi R et al. Ligation-assisted endoscopic submucosal resection with apical mucosal incision to treat gastric subepithelial tumors originating from the muscularis propria. Endoscopy 2018;50:1180–1185.PubMedCrossRef Zhang D, Lin Q, Shi R et al. Ligation-assisted endoscopic submucosal resection with apical mucosal incision to treat gastric subepithelial tumors originating from the muscularis propria. Endoscopy 2018;50:1180–1185.PubMedCrossRef
61.
go back to reference Bas-Cutrina F, Ballester-Clau R, Gonzalez-Huix F et al. Gastric perforation during ligation-assisted endoscopic mucosal resection of a neuroendocrine tumor: banding without resection may be a safer option. Endoscopy 2020;52:E370–E371.PubMedCrossRef Bas-Cutrina F, Ballester-Clau R, Gonzalez-Huix F et al. Gastric perforation during ligation-assisted endoscopic mucosal resection of a neuroendocrine tumor: banding without resection may be a safer option. Endoscopy 2020;52:E370–E371.PubMedCrossRef
62.
go back to reference Hawa F, Sako Z, Nguyen T et al. The band and slough technique is effective for management of diminutive type 1 gastric and duodenal neuroendocrine tumors. Endosc Int Open 2020;8:E717–E721.PubMedPubMedCentralCrossRef Hawa F, Sako Z, Nguyen T et al. The band and slough technique is effective for management of diminutive type 1 gastric and duodenal neuroendocrine tumors. Endosc Int Open 2020;8:E717–E721.PubMedPubMedCentralCrossRef
Metadata
Title
Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms
Authors
Xinrui Guo
Xiaohan Zhao
Gang Huang
Yanbo Yu
Publication date
16-11-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-08180-0

Other articles of this Issue 1/2024

Digestive Diseases and Sciences 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine